All In Biotech

Drug Trial Radar · NCT05658575

Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

A Multi-Center Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Last checked: Nov 20, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Jan 6, 2023

Primary completion

Dec 31, 2026

Study completion Jan 31, 2027

Sponsor

Lead sponsor
Olatec Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.

Conditions

  • Acute Gout Flare
  • Gout Attack
  • Gout Flare
  • Gouty Arthritis
  • Gout
  • Arthritis
  • Joint Pain

Interventions

  • DapansutrileDrug

    An initial loading dose of 2000 mg dapansutrile on Day 1 followed by a maintenance regimen of 1000 mg dapansutrile twice daily starting 12 hours later through the second dose on Day 7, inclusive.

  • Placebo TabletOther

    An initial loading dose of matching placebo (to mimic dapansutrile dosing) on Day 1 followed by a maintenance regimen of matching placebo twice daily starting 12 hours later through the second dose on Day 7, inclusive.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy of dapansutrile as an acute gout flare treatment compared to placebo in reducing joint pain at 72 hours post initial loading dose of IMPTime frame: 72 hours

Locations

40 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Withdrawn

  • Arizona Arthritis & Rheumatology Associates - Glendale

    Glendale, Arizona · Recruiting

  • Arizona Arthritis & Rheumatology Associates (AARA), P.C. - Mesa

    Mesa, Arizona · Recruiting

  • American Institute of Research

    Los Angeles, California · Withdrawn

  • TriWest Research Associates

    San Diego, California · Recruiting

  • Valiance Clinical Research - Tarzana

    Tarzana, California · Recruiting

  • Hillcrest Medical Research

    DeLand, Florida · Recruiting

  • SIMEDHealth

    Gainesville, Florida · Recruiting

  • University of Florida Health Jacksonville

    Jacksonville, Florida · Recruiting

  • Well Pharma Medical Research

    Miami, Florida · Recruiting

  • Clinical Research of West Florida

    Tampa, Florida · Recruiting

  • Arthritis Center of North Georgia - Gainesville

    Gainesville, Georgia · Recruiting

  • Great Lakes Clinical Trials

    Chicago, Illinois · Withdrawn

  • Advanced Quality Medical Research

    Orland Park, Illinois · Recruiting

  • The Research Group of Lexington

    Lexington, Kentucky · Active not recruiting

  • University of Michigan

    Ann Arbor, Michigan · Withdrawn

  • Montana Medical Research

    Missoula, Montana · Recruiting

  • NYU Langone

    New York, New York · Active not recruiting

  • IMA Clinical Research - Manhattan

    New York, New York · Withdrawn

  • Altoona Research

    Duncansville, Pennsylvania · Withdrawn

  • Lower Country Rheumatology - Summerville

    Summerville, South Carolina · Recruiting

  • Amarillo Center of Clinical Research

    Amarillo, Texas · Recruiting

  • Utah Health - University of Utah Hospital

    Salt Lake City, Utah · Recruiting

  • Clinical Trial Site

    Bothell, Washington · Withdrawn

  • Arthritis Northwest

    Spokane, Washington · Recruiting

  • Centre Hospitalier Universitaire de Bordeaux - Hôpital Pellegrin

    Bordeaux, France · Recruiting

  • Hôpital Saint Philibert

    Lomme, France · Recruiting

  • Hôpital Lariboisière

    Paris, France · Recruiting

  • CHU de Rouen - Hôpital Charles-Nicolle

    Rouen, France · Recruiting

  • Emek Medical Center

    Afula, Israel · Recruiting

  • Carmel Medical Center

    Haifa, Israel · Recruiting

  • Rabin Medical Center - Beilinson and Hasharon

    Petah Tikva, Israel · Recruiting

  • The Chaim Sheba Medical Center

    Ramat Gan, Israel · Recruiting

  • Reade Research BV

    Amsterdam, Netherlands · Recruiting

  • Maastricht Universitair Medisch Centrum

    Maastricht, Netherlands · Recruiting

  • VieCuri Medisch Centrum

    Venlo, Netherlands · Recruiting

  • Hospital Universitario san Juan de Alicante

    Alicante, Spain · Withdrawn

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain · Recruiting

  • Hospital Universitario de La Princesa

    Madrid, Spain · Recruiting

  • Hospital Universitario Infanta Leonor

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.